AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 29, 2023
For those with stubbornly resistant forms of severe depression, ketamine was looking more and more like a solution. Years of research has hinted at the dissociative anesthetic’s treatment potential where other medications failed, promising the benefits of electroshock therapy with far fewer risks.
BioSpace
OCTOBER 29, 2023
With recent high-profile failures, experts say safety concerns and a lack of diversification are hindering the field—but still hold out hope for an approval.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 29, 2023
Adoption of eco-friendly designs in healthcare facilities and policy interventions to address shortage of skilled human resources in healthcare is the need of the hour, says Dr. Vivek Desai, founder and managing director, HOSMAC, a hospital planning, management and design consultancy firm.
BioSpace
OCTOBER 29, 2023
In a briefing document for Tuesday’s advisory committee meeting, the FDA raised concerns about the potential off-target effects of Vertex Pharmaceuticals and CRISPR Therapeutics’ investigational gene edited therapy.
JAMA Internal Medicine
OCTOBER 29, 2023
This longitudinal cohort study measures changes in physician use of electronic health records and electronic messaging given the telemedicine expansion catalyzed by the COVID-19 pandemic.
BioSpace
OCTOBER 29, 2023
Loqtorzi is the first programmed death receptor-1 from China to be approved by the U.S. regulator, and the first for patients with recurrent or metastatic nasopharyngeal carcinoma across all lines of treatment.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
OCTOBER 29, 2023
With the potential FDA approval of an MDMA-based therapy for PTSD on the horizon, biopharma stakeholders are eyeing psychedelics with fresh anticipation.
JAMA Internal Medicine
OCTOBER 29, 2023
This case report describes a patient in their 40s with a history of end-stage kidney disease secondary to hypertension and diabetes who presented with fatigue, cough, weakness, and dyspnea on exertion and was subsequently diagnosed with acute disseminated cryptococcal infection.
BioSpace
OCTOBER 29, 2023
The Japanese pharma’s attention deficit/hyperactivity disorder candidate has shown significant symptom improvements in children and adolescents in two late-stage studies.
Roots Analysis
OCTOBER 29, 2023
Over the past decade, the rise of this digital technology has transformed various sectors, from finance to healthcare. One particular area that has seen significant innovation is the realm of clinical trials. Traditionally conducted at centralized sites like hospitals or clinics, the latest trend is moving towards decentralized clinical trials (DCTs).
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
OCTOBER 29, 2023
JLABS @ NYC Celebrates Its 5th Year in the Big Apple - read this article along with other careers information, tips and advice on BioSpace
Drug Patent Watch
OCTOBER 29, 2023
This chart shows the drugs with the most patents in Lithuania. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Lithuania? appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
OCTOBER 29, 2023
A first-in-class clinical trial will initiate this quarter to determine if a checkpoint agonist can down-regulate activated T cells to help reduce inflammation and tissue damage in patients with moderate-to-severe ulcerative colitis (UC).
FDA Law Blog
OCTOBER 29, 2023
By Michelle L. Butler — Just over two years ago, I wrote about the challenges with implementation of the contraceptive mandate in the Patient Protection and Affordable Care Act (ACA). You will recall that, despite the ACA, a 2019 HRSA Guideline , and guidance from the federal agencies responsible for enforcing the contraceptive coverage requirement of the ACA (the Departments), women seeking contraceptives that were not specifically identified on an FDA Birth Control Guide were encountering roa
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
214 
Let's personalize your content